advantage, 100 mg/ml užlašinamasis tirpalas katėms
bayer animal health gmbh (vokietija) - užlašinamasis tirpalas - 1 ml tirpalo yra: imidakloprido - 100 mg. - katėms, užsikrėtusioms blusomis, gydyti ir užsikrėtimo profilaktikai. vieną kartą gydyta katė blusomis neužsikrečia 4 sav. vaistą galima naudoti kaip papildomą priemonę blusų sukeltam alerginiam dermatitui (bad) kontroliuoti.
credelio plus
elanco gmbh - lotilaner, milbemycin oxime - endektokidai - Šunys - for use in dogs with, or at risk from, mixed infestations/infections of ticks, fleas, gastrointestinal nematodes, heartworm and/or lungworm.
rilonacept regeneron (previously arcalyst)
regeneron uk limited - rilonacept - cryopyrin susijusių periodiškai sindromai - imunosupresantai - rilonaceptas regeneron skirtas su kriopirinu susiję periodiniai sindromai (sksps) gydymui su sunkiu ligos simptomai, įskaitant šeiminės šalčio autoimunine sindromo (ŠŠas) ir muckle wells sindromas (mws), suaugusiesiems ir vaikams nuo 12 metų ir vyresnio amžiaus.
fentrol
uab „dezinfa“, a. smetonos al. 67b, lt-45309 kaunas - difenakumas - veikliosios medžiagos cas nr.: 56073-07-5, eb nr.: 259-978-4, veikliosios medžiagos pavadinimas: difenakumas, koncentracija: 0.005% , veiklioji - rodenticidai
fentrol bait blocks
uab „dezinfa“, a. smetonos al. 67b, lt-45309 kaunas - difenakumas - veikliosios medžiagos cas nr.: 56073-07-5, eb nr.: 259-978-4, veikliosios medžiagos pavadinimas: difenakumas, koncentracija: 0.005% , veiklioji - rodenticidai
roferon-a
roche lietuva, uab - interferonas alfa-2a - injekcinis tirpalas užpildytame švirkšte - 3000000 tv - interferon alfa-2a
roferon-a
nenurodyta - interferonas alfa-2a - injekcinis tirpalas užpildytame švirkšte - 3 mln. tv - interferon alfa-2a
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - karcinoma, plazminė ląstelė - antinavikiniai vaistai - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
alpheon
biopartners gmbh - recombinant human interferon alfa-2a - hepatitas c, lėtinis - immunostimulants, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation. the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.